The Atypical Cannabinoid Abn-CBD Reduces Inflammation and Protects Liver, Pancreas, and Adipose Tissue in a Mouse Model of Prediabetes and Non-alcoholic Fatty Liver Disease.

Abstract

Background and Aims: The synthetic atypical cannabinoid Abn-CBD, a cannabidiol (CBD) derivative, has been recently shown to modulate the immune system in different organs, but its impact in obesity-related meta-inflammation remains unstudied. We investigated the effects of Abn-CBD on metabolic and inflammatory parameters utilizing a diet-induced obese (DIO) mouse model of prediabetes and non-alcoholic fatty liver disease (NAFLD). Materials and Methods: Ten-week-old C57Bl/6J mice were fed a high-fat diet for 15 weeks, following a 2-week treatment of daily intraperitoneal injections with Abn-CBD or vehicle. At week 15 mice were obese, prediabetic and developed NAFLD. Body weight and glucose homeostasis were monitored. Mice were euthanized and blood, liver, adipose tissue and pancreas were collected and processed for metabolic and inflammatory analysis. Results: Body weight and triglycerides profiles in blood and liver were comparable between vehicle- and Abn-CBD-treated DIO mice. However, treatment with Abn-CBD reduced hyperinsulinemia and markers of systemic low-grade inflammation in plasma and fat, also promoting white adipose tissue browning. Pancreatic islets from Abn-CBD-treated mice showed lower apoptosis, inflammation and oxidative stress than vehicle-treated DIO mice, and beta cell proliferation was induced. Furthermore, Abn-CBD lowered hepatic fibrosis, inflammation and macrophage infiltration in the liver when compared to vehicle-treated DIO mice. Importantly, the balance between hepatocyte proliferation and apoptosis was improved in Abn-CBD-treated compared to vehicle-treated DIO mice. Conclusions: These results suggest that Abn-CBD exerts beneficial immunomodulatory actions in the liver, pancreas and adipose tissue of DIO prediabetic mice with NAFLD, thus protecting tissues. Therefore, Abn-CBD and related compounds could represent novel pharmacological strategies for managing obesity-related metabolic disorders.

• Authors: Silvana Y Romero-Zerbo, María García-Fernández, Vanesa Espinosa-Jiménez, Macarena Pozo-Morales, Alejandro Escamilla-Sánchez, Lourdes Sánchez-Salido, Estrella Lara, Nadia Cobo-Vuilleumier, Alex Rafacho, Gabriel Olveira, Gemma Rojo-Martínez, Benoit R Gauthier, Isabel González-Mariscal, Francisco J Bermúdez-Silva
• Journal: Frontiers in endocrinology (Front Endocrinol (Lausanne)) Vol. 11 Pg. 103 ( 2020) ISSN: 1664-2392 [Print] Switzerland
• PMID: 32210914 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2020 Romero-Zerbo, García-Fernández, Espinosa-Jiménez, Pozo-Morales, Escamilla-Sánchez, Sánchez-Salido, Lara, Cobo-Vuilleumier, Rafacho, Olveira, Rojo-Martínez, Gauthier, González-Mariscal and Bermúdez-Silva.

Chemical References

• 4-(3-3,4-p-menthadien-(1,8)-yl)olivetol
• Resorcinols

Topics

• Adipose Tissue (drug effects, metabolism, pathology)
• Animals
• Cytoprotection (drug effects)
• Diet, High-Fat
• Disease Models, Animal
• Inflammation (etiology, pathology, prevention & control)
• Liver (drug effects, metabolism, pathology)
• Male
• Mice
• Mice, Inbred C57BL
• Mice, Obese
• Non-alcoholic Fatty Liver Disease (drug therapy, etiology, metabolism, pathology)
• Obesity (complications, drug therapy, metabolism)
• Pancreas (drug effects, metabolism, pathology)
• Prediabetic State (drug therapy, etiology, metabolism, pathology)
• Resorcinols (pharmacology, therapeutic use)